



UNLOCKING NATURE'S HEALING POTENTIAL



Medikvault® Dosi Bow

PRODUCT INFORMATION LEAFLET for Healthcare Professionals

1. PRODUCT DETAILS

Product Form:

Dried Whole Cannabis Flower

Container:

10g medical grade plastic jar with childproof lid

Composition:


- THC(Delta-9-Tetrahydrocannabinol): 27.91% w/w
- CBD(Cannabidiol): <1%w/w (<10mg/g)
- Appearance: Light green flower buds with glandular trichomes and characteristic aroma



1.1 Active Components Primary Cannabinoids

THC	27.91%
CBDV	Not Detected
THCV	0.68%
CBD	0.08%
CBC	0.07%
Δ8-THC	Not Detected
Δ9-THC	27.91%
CBG	0.39%
CBN	0.18%

1.2 THC Meter




CBG 0.39%

CBN 0.18%

CBD 0.08%

CBC 0.07%

1.3 Terpene Profile



2. DOSING AND ADMINISTRATION


2.1 General Guidelines

- Use only with TGA approved medical cannabis vaporiser
- Product requires heating for decarboxylation
- "START LOW and GO SLOW" approach
- Monitor for clinical effect and adverse events

2.2 Initial Dosing

It is recommended that patients start with 1 inhalation, wait 15 minutes, and then increase by 1 inhalation every 15-30 minutes until clinical effect and as tolerated, to the recommended maximum daily dose. In inhalation products, the recommended maximum dose of THC should be 500mg per day (as per the VIC Government Safe Script)

- Increase every 1-2 days until desired effect
- May take 1-2 months to optimise
- New users:
 - Single inhalation initially
 - Wait 10-20 minutes before next inhalation
 - Consider lower starting dose and slower titration
- Start at lowest effective dose, use medium temperature
- Single inhalation: 5-sec draw, 10-sec hold, gentle exhale
- Onset: 5-10 min, Peak: 30-60 min, Duration: 2-4 hr, Clearance: Up to 12 hr



MEDIKvault® Dosi Bow

PRODUCT INFORMATION LEAFLET for Healthcare Professionals

Medication Titration Schedule (Maximum 500mg THC Daily)

Time Period	Morning Max	Evening Max	Total Max Daily Dose	Notes
Day 1-3	125mg	125mg	250mg	Maintain minimum 3 hours between doses
Day 4-7	125mg	250mg	375mg	Increase morning dose if tolerated
Week 2+	250mg	250mg	500mg	Maximum daily dose

Important Note:

- Maximum daily dose: 500mg (250mg morning + 250mg evening)
- Maintain minimum 3 hours between doses
- Adjust titration based on individual response and tolerability
- Do not exceed maximum daily dose of 500mg

2.3 Factors Affecting Response

- Depth of inhalation
- Length of inhalation
- Breath hold duration
- Individual patient variation

2.4 Vapourisation Temperature Guide

High 205 - 221 C		Maximum extraction of cannabinoids providing strongest psychoactive effects
Medium 178 - 204 C		Recommended starting temperature
Low 163 - 177 C		Gentler on the throat with potentially subdued psychoactive effects

3. SAFETY PROFILE

3.1 Adverse Events

Side Effects by Frequency

FREQUENCY	
Very Common	Drowsiness/fatigue, dizziness, dry mouth, anxiety, nausea, cough/phlegm, bronchitis, cognitive effects
Common	Euphoria, blurred vision, headache
Uncommon	Hypotension, paranoia, depression, tachycardia, diarrhoea, hyperemesis

Frequency Definitions:

- Very Common:** affects more than 1 in 10 people
- Common:** affects up to 1 in 10 people
- Uncommon:** affects up to 1 in 100 people

3.2 Drug Interactions

Drug Class	Interaction Type	Risk Level	Management
CNS Depressants	Pharmacodynamic	High	Avoid combination
Benzodiazepines	Additive	High	Avoid/reduce dose
Opioids	Synergistic	High	Close monitoring
Alcohol	Additive	High	Contraindicated
Warfarin	Pharmacokinetic	Moderate	Monitor INR
SSRIs	Variable	Low - Moderate	Monitor
Antipsychotics	Complex	Moderate	Individual assessment

Metabolic Interactions & Monitoring Guidelines

Hepatic Cytochrome P450 System:


- CYP2C9
- CYP2C19
- CYP1A2
- CYP3A4

3.3 High Risk Drug Interactions

Interaction Type	Medications	Effects/Notes
Enhanced Effects	Tricyclic antidepressants Sympathomimetic agents Anticholinergics Warfarin	Increased tachycardia Hypertension risk Enhanced drowsiness Elevated drug levels
Increased Bioavailability	Bupropion Paroxetine Quinidine CYP inhibitors Clomethiazole Disulfiram	Monitor for increased side effects and adjust dose as needed
Decreased Effectiveness	Rifampicin Carbamazepine Phenobarbital Phenytoin St John's Wort	May require dose adjustment or alternative treatment

3.4 Monitoring Protocol

Initial Assessment	Baseline medical evaluation Mental health assessment Substance use history
Ongoing Monitoring	Side effect tracking Treatment efficacy Dose adjustments Quality of life assessment Dependence monitoring



MEDIKvault® Dosi Bow

PRODUCT INFORMATION LEAFLET for Healthcare Professionals

3.5 Contraindications

Not recommended for patients with:

1. Hypersensitivity to cannabinoids or excipients
2. Pregnancy, planning pregnancy, or breastfeeding
3. Psychiatric conditions:
 - Known or suspected history of schizophrenia
 - Family history of schizophrenia
 - Severe personality disorder
 - Significant psychiatric disorders (except depression associated with an underlying condition)
4. Cardiovascular conditions:
 - Unstable cardiovascular disease
 - Severe cardiopulmonary disease
 - History of hypotension, hypertension, syncope, or tachycardia
5. Severe immunological, liver, or kidney disease (especially in acute states)

4. PHARMACOLOGY

4.1 Mechanism of Action

- THC is responsible for intoxicating and psychoactive effects
- THC may provide medicinal effects including:
 - Reducing nausea and vomiting
 - Pain relief
 - Muscle spasm reduction
 - Sleep improvement
 - Appetite stimulation
- CBD is not known to be intoxicating

4.2 Pharmacokinetics and Pharmacodynamics

- Absorption: Direct from pulmonary tissue into bloodstream
- Onset: 5-10 minutes after inhalation
- Peak effects: Approximately 60 minutes after inhalation
- Duration: 2-4 hours
- Notes:
 - Avoids initial liver metabolism
 - Considerable variation in absorption between patients
 - Rapid onset allows for quick dose titration

5. OVERDOSE SYMPTOMS AND MANAGEMENT

5.1 Symptoms

- Chest pain
- Rapid heartbeat
- Psychotic episode

- Respiratory depression
- Severe anxiety/panic attack
- Ataxia
- Slurred speech
- Potential coma

5.2 Management

- Children are at greater risk of poisoning
- Contact Poisons Information Centre: 13 11 26 (Australia)
- Seek immediate medical attention

6. DRIVING AND MACHINERY OPERATION

6.1 Restrictions

- Do not drive after use until the effects are known
- Do not operate heavy machinery
- No established safe waiting period
- Drug-driving may be a criminal offense

6.2 Effects on Operation

- May cause drowsiness
- May impair concentration
- May affect decision-making ability
- Cannabinoids detectable for multiple hours

7. REPORTING ADVERSE EVENTS

Report to:

- Therapeutic Goods Administration
(<https://www.tga.gov.au/safety/reporting-problems>)
- For overdose: Poisons Information Centre
13 11 26 (Australia)

DISTRIBUTION AND CONTACT

©MEDIKvault® Dosi Bow is distributed by PlantOgram Pty. Ltd.

ABN: 24 677 154 684

Email: support@plantogram.com.au

This leaflet was prepared in September 2025